BaseLaunch funds four healthcare ventures
BaseLaunch supports carefully selected ventures in two phases. After an intense pressure test period, four projects were selected for Phase II of our second year. They now have the opportunity to further advance their breakthrough healthcare innovation and secure further investment.
The four healthcare ventures Anaveon, Pattern Biosciences, Synendos Therapeutics and a biotech in stealth mode receive funding of up to 250,000 Swiss francs as well as further support from BaseLaunch and its partners. Additionally, these projects have free-of-charge access to BaseLaunch’s co-working space and fully equipped shared laboratory in the Switzerland Innovation Park Basel Area in Allschwil.
This package allows the teams to focus on what truly matters: advancing and de-risking their science and further developing their ventures.
Applications for the BaseLaunch accelerator 2019 are now open
Further, BaseLaunch opens the next round of its accelerator program. The initiative, managed by BaselArea.swiss, is looking for people and projects with breakthrough healthcare innovations mainly in the field of therapeutics. However, applications are also open for game-changing innovation in diagnostics, medtech or related fields.
During Phase I, the selected projects develop their cases in Basel while having access to up to 10,000 Swiss francs each for consultancy and other services.
Phase II lasts at least twelve months, with each project receiving funding of up to 250,000 Swiss francs for further developing their venture.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More